Ophthalmic medical tech firm RxSight Q2 revenue falls

Reuters

Aug 08

Ophthalmic medical tech firm RxSight <a href="https://laohu8.com/S/QTWO">Q2</a> revenue falls

Overview

RxSight Q2 2025 revenue falls 4% to $33.6 mln, LDD sales drop 50%
Net loss widens to $11.8 mln from $6.1 mln in Q2 2024
Gross profit rises due to favorable product mix shift, operating expenses up 20%

Outlook

Company reiterates 2025 revenue guidance of $120 mln to $130 mln
RxSight expects 2025 gross margin between 72% and 74%
Operating expenses for 2025 projected at $145 mln to $155 mln
Non-cash stock-based compensation expected at $27 mln to $30 mln

Result Drivers

LAL SALES - 13% increase in Light Adjustable Lens sales contributed to higher gross profit margin
LDD SALES DECLINE - 50% decrease in Light Delivery Device sales impacted overall revenue
FDA APPROVAL - Expansion of LAL dioptric power range and new software updates received FDA approval

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Gross Profit		$25.20 mln
Q2 Operating Expenses		$39.20 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 8 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Rxsight Inc is $9.00, about 16.1% above its August 6 closing price of $7.55

Press Release: ID:nGNX9BnXqC

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557290591"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557290591\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557290591?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557290591","market":"fut","top_or_hot":-1,"title":"Ophthalmic medical tech firm RxSight Q2 revenue falls","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Ophthalmic medical tech firm RxSight <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue falls </title></head><body><p><span>Overview</span></p><ul><li><p>RxSight Q2 2025 revenue falls 4% to $33.6 mln, LDD sales drop 50%</p></li><li><p>Net loss widens to $11.8 mln from $6.1 mln in Q2 2024</p></li><li><p>Gross profit rises due to favorable product mix shift, operating expenses up 20%</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company reiterates 2025 revenue guidance of $120 mln to $130 mln</p></li><li><p>RxSight expects 2025 gross margin between 72% and 74%</p></li><li><p>Operating expenses for 2025 projected at $145 mln to $155 mln</p></li><li><p>Non-cash stock-based compensation expected at $27 mln to $30 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LAL SALES - 13% increase in Light Adjustable Lens sales contributed to higher gross profit margin</p></li><li><p>LDD SALES DECLINE - 50% decrease in Light Delivery Device sales impacted overall revenue</p></li><li><p>FDA APPROVAL - Expansion of LAL dioptric power range and new software updates received FDA approval</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Gross Profit</p></td><td></td><td><p>$25.20 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$39.20 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 8 \"hold\" and 2 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Rxsight Inc is $9.00, about 16.1% above its August 6 closing price of $7.55</p></li></ul><p>Press Release: <span>ID:nGNX9BnXqC</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ophthalmic medical tech firm RxSight Q2 revenue falls</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOphthalmic medical tech firm RxSight Q2 revenue falls\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-08 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Ophthalmic medical tech firm RxSight <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue falls </title></head><body><p><span>Overview</span></p><ul><li><p>RxSight Q2 2025 revenue falls 4% to $33.6 mln, LDD sales drop 50%</p></li><li><p>Net loss widens to $11.8 mln from $6.1 mln in Q2 2024</p></li><li><p>Gross profit rises due to favorable product mix shift, operating expenses up 20%</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company reiterates 2025 revenue guidance of $120 mln to $130 mln</p></li><li><p>RxSight expects 2025 gross margin between 72% and 74%</p></li><li><p>Operating expenses for 2025 projected at $145 mln to $155 mln</p></li><li><p>Non-cash stock-based compensation expected at $27 mln to $30 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LAL SALES - 13% increase in Light Adjustable Lens sales contributed to higher gross profit margin</p></li><li><p>LDD SALES DECLINE - 50% decrease in Light Delivery Device sales impacted overall revenue</p></li><li><p>FDA APPROVAL - Expansion of LAL dioptric power range and new software updates received FDA approval</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Gross Profit</p></td><td></td><td><p>$25.20 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$39.20 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 8 \"hold\" and 2 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Rxsight Inc is $9.00, about 16.1% above its August 6 closing price of $7.55</p></li></ul><p>Press Release: <span>ID:nGNX9BnXqC</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMI","symbol_name":"康明斯","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLXFC48CB:2","article_id":"2557290591","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557290591","pubTimestamp":1754600722,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ophthalmic medical tech firm RxSight Q2 revenue fallsOverviewRxSight Q2 2025 revenue falls 4% to $33.6 mln, LDD sales drop 50%Net loss widens to $11.8 mln from $6.1 mln in Q2 2024Gross profit rises du","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CMI":"康明斯","RXST":"RxSIGHT, INC."},"translate_title":"眼科医疗科技公司RxSight第二季度收入下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMI":0.9,"RXST":0.9},"content_text":"Ophthalmic medical tech firm RxSight Q2 revenue falls OverviewRxSight Q2 2025 revenue falls 4% to $33.6 mln, LDD sales drop 50%Net loss widens to $11.8 mln from $6.1 mln in Q2 2024Gross profit rises due to favorable product mix shift, operating expenses up 20%OutlookCompany reiterates 2025 revenue guidance of $120 mln to $130 mlnRxSight expects 2025 gross margin between 72% and 74%Operating expenses for 2025 projected at $145 mln to $155 mlnNon-cash stock-based compensation expected at $27 mln to $30 mlnResult DriversLAL SALES - 13% increase in Light Adjustable Lens sales contributed to higher gross profit marginLDD SALES DECLINE - 50% decrease in Light Delivery Device sales impacted overall revenueFDA APPROVAL - Expansion of LAL dioptric power range and new software updates received FDA approvalKey DetailsMetricBeat/MissActualConsensus EstimateQ2 Gross Profit$25.20 mlnQ2 Operating Expenses$39.20 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 8 \"hold\" and 2 \"sell\" or \"strong sell\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy.\"Wall Street's median 12-month price target for Rxsight Inc is $9.00, about 16.1% above its August 6 closing price of $7.55Press Release: ID:nGNX9BnXqC(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}